Business Context and Reporting Period
This Form 8-K Current Report was filed by SELLAS Life Sciences Group, Inc. on April 16, 2018, regarding corporate governance changes effective April 20, 2018. The filing details the departure of the Interim Chief Financial Officer and the appointment of a new Chief Financial Officer.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
- Departure of Interim CFO: Aleksey Krylov ceased his role as Interim Chief Financial Officer effective April 20, 2018. He agreed to remain with the finance team until July 15, 2018, to assist with the transition.
- Appointment of New CFO: Gene Mack was appointed Chief Financial Officer and Treasurer effective April 20, 2018.
Guidance, Outlook, and Compensation Details
The filing outlines the compensation package for the new CFO, Gene Mack, under a letter agreement:
- Base Salary: $335,000 annually, subject to board review.
- Discretionary Bonus: Target amount of up to 40% of base salary, contingent on performance objectives.
- Equity Grant: Incentive stock options to purchase 40,000 shares of common stock. The exercise price equals the closing market price on April 20, 2018.
- Vesting Schedule: 25% vests on April 20, 2019, with the remainder vesting monthly (1/48th) over the subsequent 36 months, totaling a 4-year vesting period.
- Employment Terms: The agreement has no specified term and allows termination by either party with written notice. A formal Employment Agreement addressing termination benefits and change of control provisions is expected to be finalized in the near future.
Investor Verification Checklist
- Verify the closing market price of SELLAS Life Sciences Group, Inc. common stock on April 20, 2018, to determine the exercise price of the 40,000 options granted to Mr. Mack.
- Monitor future filings for the formal Employment Agreement to confirm specific termination benefits and change of control provisions.
- Review the company's 2017 Equity Incentive Plan to understand the total pool of shares available for future grants.